[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Viatris Inc (VTRS)

Viatris Inc (VTRS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Market News and Commentary

How Is Viatris’ Stock Performance Compared to Other Healthcare Stocks?

Viatris Inc. (VTRS) is a global healthcare powerhouse dedicated to expanding access to high-quality medicines and helping people live healthier lives at every stage. Leveraging a diverse portfolio that spans generics, established brands, and innovative therapies, the company addresses a wide range of healthcare needs, including areas with significant unmet demand. Backed by a global footprint, Viatris combines scale, innovation, and supply-chain resilience to deliver sustainable healthcare solutions to patients worldwide.

With a market value of roughly $17.89 billion, Viatris comfortably qualifies as a large-cap stock. Its sizable valuation not only exceeds the $10 billion benchmark for large-cap companies but...

Fundamentals

See More
  • Market Capitalization, $K 17,899,178
  • Shares Outstanding, K 1,164,553
  • Annual Sales, $ 14,300 M
  • Annual Income, $ -3,515 M
  • EBIT $ 139 M
  • EBITDA $ 5,875 M
  • 60-Month Beta 0.90
  • Price/Sales 1.28
  • Price/Cash Flow 2.13
  • Price/Book 1.25

Options Overview Details

View History
  • Implied Volatility 37.41% (+6.75%)
  • Historical Volatility 38.14%
  • IV Percentile 49%
  • IV Rank 39.74%
  • IV High 54.04% on 02/18/26
  • IV Low 26.44% on 12/23/25
  • Expected Move (DTE 28) 0.92 (5.97%)
  • Put/Call Vol Ratio 5.08
  • Today's Volume 21,270
  • Volume Avg (30-Day) 3,677
  • Put/Call OI Ratio 0.46
  • Today's Open Interest 158,863
  • Open Int (30-Day) 151,004
  • Expected Range 14.45 to 16.29

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $0.62
  • Number of Estimates 4
  • High Estimate $0.63
  • Low Estimate $0.62
  • Prior Year $0.62
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
14.94 +2.88%
on 06/18/26
16.76 -8.29%
on 05/26/26
-1.13 (-6.85%)
since 05/18/26
3-Month
12.87 +19.43%
on 03/30/26
17.53 -12.32%
on 05/14/26
+1.63 (+11.86%)
since 03/18/26
52-Week
8.63 +78.20%
on 08/01/25
17.53 -12.32%
on 05/14/26
+6.60 (+75.26%)
since 06/18/25

Most Recent Stories

More News
How Is Viatris’ Stock Performance Compared to Other Healthcare Stocks?

Viatris has outperformed its industry peers over the past year, and Wall Street appears optimistic about the stock.

XLV : 149.40 (-0.87%)
VTRS : 15.37 (-2.29%)
ANIP : 79.49 (-1.28%)
1 Cash-Producing Stock with Exciting Potential and 2 Facing Headwinds

1 Cash-Producing Stock with Exciting Potential and 2 Facing Headwinds

MGNI : 17.89 (-1.92%)
VFC : 17.33 (+3.77%)
VTRS : 15.37 (-2.29%)
How Is Zoetis’ Stock Performance Compared to Other Healthcare Stocks?

Zoetis has underperformed its industry peers over the past year, yet Wall Street remains optimistic about the stock.

XLV : 149.40 (-0.87%)
VTRS : 15.37 (-2.29%)
ZTS : 78.71 (+1.88%)
1 Unpopular Stock That Should Get More Attention and 2 We Find Risky

1 Unpopular Stock That Should Get More Attention and 2 We Find Risky

MSM : 118.51 (+2.89%)
VTRS : 15.37 (-2.29%)
PL : 28.23 (+0.04%)
Viatris (VTRS): Buy, Sell, or Hold Post Q1 Earnings?

Viatris (VTRS): Buy, Sell, or Hold Post Q1 Earnings?

VTRS : 15.37 (-2.29%)
U.S. FDA Accepts Viatris New Drug Application for Fast-Acting Meloxicam for the Treatment of Moderate-to-Severe Acute Pain

FDA PDUFA Goal Date Set for Dec. 27, 2026

VTRS : 15.37 (-2.29%)
1 Stock Under $50 to Target This Week and 2 We Avoid

1 Stock Under $50 to Target This Week and 2 We Avoid

ZUMZ : 17.79 (+1.89%)
VTRS : 15.37 (-2.29%)
LC : 19.21 (+2.13%)
5 Revealing Analyst Questions From Viatris’s Q1 Earnings Call

5 Revealing Analyst Questions From Viatris’s Q1 Earnings Call

VTRS : 15.37 (-2.29%)
3 Unprofitable Stocks That Fall Short

3 Unprofitable Stocks That Fall Short

NNBR : 2.79 (+0.36%)
VTRS : 15.37 (-2.29%)
MRCY : 113.91 (-1.38%)
VTRS Q1 Deep Dive: China Strength, R&D Pipeline, and Execution Drive Outperformance

VTRS Q1 Deep Dive: China Strength, R&D Pipeline, and Execution Drive Outperformance

VTRS : 15.37 (-2.29%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Viatris, Inc. is a global healthcare company. Its portfolio comprises more than thousand approved molecules across a wide range of key therapeutic areas, including globally recognized iconic and key brands, generic, complex generic, and biosimilar products. Branded products include EpiPen, Amitiza, Lipitor...

See More

Key Turning Points

3rd Resistance Point 17.26
2nd Resistance Point 16.71
1st Resistance Point 16.04
Last Price 15.37
1st Support Level 14.82
2nd Support Level 14.27
3rd Support Level 13.60

See More

52-Week High 17.53
Last Price 15.37
Fibonacci 61.8% 14.13
Fibonacci 50% 13.08
Fibonacci 38.2% 12.03
52-Week Low 8.63

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.